Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy

Blood

Volumn 101, Issue 10, 2003, Pages 3794-3800

  Cortes, Jorge E ^a   Talpaz, Moshe ^b   Giles, Francis ^b   O'Brien, Susan ^b   Rios, Mary Beth ^b   Shan, Jianqin ^b   Garcia Manero, Guillermo ^b   Faderl, Stefan ^b   Thomas, Deborah A ^b   Wierda, William ^b   Ferrajoli, Allessandra ^b   Jeha, Sima ^b   Kantarjian, Hagop M ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CHROMOSOME 7; CHROMOSOME ABERRATION; CHROMOSOME DELETION 5; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CLONE; CONTROLLED STUDY; CYTOGENETICS; DISEASE SEVERITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PATHOPHYSIOLOGY; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; STATISTICAL ANALYSIS; TRISOMY 8; AGE; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; MYELOID LEUKEMIA; ONSET AGE; PATHOLOGY; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; SPLENOMEGALY; SURVIVAL; TIME;

AGE FACTORS; AGE OF ONSET; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; HUMANS; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MIDDLE AGED; PATIENT SELECTION; PIPERAZINES; PROGNOSIS; PYRIMIDINES; SPLENOMEGALY; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 0012906888     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-09-2790     Document Type: Article

References (45)

1. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic myelogenous leukemia: a concise update. Blood. 1993;82:691-703.
2. Kantarjian HM, O'Brien S, Anderlini P, Talpaz M. Treatment of myelogenous leukemia: current status and investigational options. Blood. 1996;87: 3069-3081.
3. Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia: biology and therapy. Ann Intem Med. 1999;131:207-219.
4. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341:164-172.
5. Kantarjian HM, Dixon D, Keating MJ, et al. Characteristics of accererated disease in chronic myelogenous leukemia. Cancer. 1988;61:1441-1446.
6. Kantarjian HM, Keating MJ, Talpaz M, et al. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med. 1987;83:445-454.
7. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990;247:824-830.
8. Kelliher MA, McLaughlin J, Witte ON, Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci U S A. 1990;87:6649-6653.
9. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med. 1995;122:254-261.
10. Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet. 1995; 345:1392-1397.
11. Long-term follow-up of the Italian trial of interferon-alpha versus conventional chemotherapy in chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Blood. 1998;92:1541-1548.
12. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group. J Natl Cancer Inst. 1997;89:1616-1620.
13. Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med. 1997;337:223-229.
14. Kantarjian HM, O'Brien S, Smith TL, et al. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. J Clin Oncol. 1999;17:284-292.
15. Kantarjian HM, Giles FJ, O'Brien S, Giralt S, Talpaz M. Therapeutic choices in younger patients with chronic myelogenous leukemia. Cancer. 2000;89:1647-1658.
16. Silver RT, Woolf SH, Hehlmann R, et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood. 1999;94:1517-1536.
17. Goldman JM, Szydlo R, Horowitz MM, et al. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood. 1993;82:2235-2238.
18. Gratwohl A, Hermans J, Niederwieser D, et al. Bone marrow transplantation for chronic myeloid leukemia: lorg-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant. 1993;12:509-516.
19. Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 1998;352:1087-1092.
20. Hansen JA, Gooley TA, Martin PJ, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med. 1998;338:962-968.
21. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566.
22. Beran M, Cao X, Estrov Z, et al. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res. 1998;4:1661-1672.
23. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
24. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001; 344:1038-1042.
25. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652.
26. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hemtologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2000;99:1928-1937.
27. Sawyers C, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99:3530-3539.
28. Kantarjian H, Talpaz M, O'Brien S, et al. Imatinib mesylate for Philadeiphia chromosome-positive, chronic phase myeloid leukemia after failure of interferon-α: follow-up results. Clin Cancer Res. 2002;8:2177-2187.
29. Kantarjian H, O'Brien S, Cortes J, et al. Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res. 2002;8: 2167-2176.
30. Kantarjian H, Cortes J, O'Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood. 2002;99:3547-3553.
31. Anastasi J, Feng J, Le Beau M, et al. The relationship between secondary chromosomal abnormalities and blast transformation in chronic myelogenous leukemia. Leukemia. 1995;9:628-633.
32. Sessarego M, Panarello C, Coviello DA, et al. Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. Cancer Genet Cytogenet. 1987;25:73-80.
33. Swolin B, Weinfeld A, Westin J, et al. Karyotypic evolution in Ph-positive chronic myeloid leukemia in relation to management and disease progression. Cancer Genet Cytogenet. 1985;18:65-79.
34. Kantarjian H, Smith TL, McCredie KB, et al. Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. Blood. 1985;66: 1326-1335.
35. Sokal JE, Gomez GA, Baccarani M, et al. Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia. Blood. 1988;72:294-298.
36. Johansson B, Fioretos T, Billström R, Mitelman F. Aberrant cytogenetic evolution pattern of Philadelphia-positive chronic myeloid leukemia treated with interferon-α. Leukemia. 1996;10:1134-1138.
37. Fayad L, Kantarjian H, O'Brien S, et al. Emergence of new clonal abnormalities following interferon-alpha induced complete cytogeneteic response in patients with chronic myeloid leukemia: report of three cases. Leukemia. 1997;11:767-771.
38. Majlis A, Smith TL, Talpaz M, O'Brien S, Rios MB, Kantariian HM. Significance of cytogenetic clonal evolution in chronic myelogenous leukemia. J Clin Oncol. 1996;14:196-203.
39. Cortes J, Talpaz M, O'Brien S, et al. Suppression of cytogenetic clonal evolution with interferon alfa therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. J Clin Oncol. 1998;16:3279-3285.
40. Przepiorka D, Thomas ED. Prognostic significance of cytogenetic abnormalities in patients with chronic myelogenous leukemia. Bone Marrow Transplant. 1988;3:113-119.
41. O'Dwyer M, Mauro M, Kurilik G, et al. The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood. 2002;100:1628-1633.
42. Larson R. Imatinib (STI571, Gleevec) as initial therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia (CML): results of a randomized phase III study vs. interferon-alfa + cytarabine (IFN + AraC) [abstract]. Blood. 2002; 100:2.
43. Medina J, Kantarjian H, Talpaz M, et al. Chromosomal abnormalities in Philadelphia chromosome (Ph) negative metaphases appearing during treatment with imatinib mesylate in patients (pts) with Ph positive chronic myeloid leukemia (CML) in chronic phase (CP) [abstract]. Blood. 2002: 100:1423.
44. Marktel S, Marin D, Foot N, et al. Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression [abstract]. Blood. 2002;100:3104.
45. Sun G, Boczkowska B, Tsheurekdjian L, Lorenzo M, Owens M. The emergence of cytogenetically unrelated clones may not be an uncommon finding in imatinib mesylate-treated CML [abstract]. Blood. 2002;100:4855.